No surprises but it's still bad news - EU medtech reforms
This article was originally published in SRA
“No surprises in draft report on medical devices from Rapporteur Roth-Behrendt.” That was the title of the press release issued by the EU medtech industry association, Eucomed, in response to the latest phase in the EU medtech regulatory reforms process.
You may also be interested in...
The European public assessment report for Novartis's advanced breast cancer therapy, Piqray (alpelisib), includes some interesting insights into what EU regulators are looking for in drug company clinical trials.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
The loss of fast-track status for setmelanotide at the European Medicines Agency means the review of the potential treatment of two rare genetic disorders of obesity will take longer than Rhythm Pharmaceuticals had originally hoped.